Hizentra® in Inflammatory Neuropathies - pHeNIx Study

Launched by CSL BEHRING · Dec 11, 2020

Keywords

ClinConnect Summary

The pHeNIx study is looking at how well Hizentra®, a treatment for a condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), works when patients switch from receiving it through an IV (a tube) to a subcutaneous (under the skin) method. This study aims to understand how this switch can be done in everyday practice, how well patients tolerate the new method, and how effective it is in helping them feel better. Participants will use a special app to share their experiences and symptoms during the study.

To be eligible for this study, participants must be adults aged 18 and older who have been diagnosed with CIDP and are planning to switch from IV immunoglobulin treatment to Hizentra®. They should have received at least three courses of IV immunoglobulin and have been stable in their treatment for the past three months. Additionally, participants need to have access to a smartphone, tablet, or computer to use the app. If you or someone you know fits these criteria and is interested, this study may be a great opportunity to help improve treatment options for CIDP.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patient (aged ≥18 years)
• • Patients suffering from CIDP according to EAN/PNS 2021 criteria
• • Planned switch from IVIg to Hizentra®
• • Patient treated with at least 3 courses of IV immunoglobulin and deemed by the investigator to be dependent on immunoglobulins
• • Patient deemed to be stable, with no change in their treatment for the disease during the 3 months prior to inclusion
• • Patients who have a smartphone, a tablet or a computer
• • Patients who have been informed verbally and in writing of the purposes of the study
• Exclusion Criteria:
• • Concomitant participation in an interventional clinical study